Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Molecular Profile | MSH2 loss |
| Therapy | N/A |
| Indication/Tumor Type | endometrial carcinoma |
| Response Type | not applicable |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|---|---|---|---|---|---|---|
| MSH2 loss | endometrial carcinoma | not applicable | N/A | Preclinical | Emerging | Preclinical shRNA mediated-inhibition of POLB in human endometrial carcinoma cells with MSH2 loss resulted in synthetic lethality, suggesting POLB may be a promising therapeutic target for MSH2 deficient cancer cells (PMID: 20227038). | 20227038 |
| PubMed Id | Reference Title | Details |
|---|---|---|
| (20227038) | DNA polymerases as potential therapeutic targets for cancers deficient in the DNA mismatch repair proteins MSH2 or MLH1. | Full reference... |